Cipla launches CiplaMed 2.0 – knowledge sharing platform for healthcare practitioners (HCPs)
This initiative underscores the growing importance of digital platforms in the medical education and the use of technology…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
17 Aug 23
This initiative underscores the growing importance of digital platforms in the medical education and the use of technology…
16 Aug 23
The trial showed therapeutic equivalence in mean change of best corrected visual acuity (BCVA) from baseline to week…
16 Aug 23
MN-001 is an orally administered, small molecule compound with many mechanisms of action to treat chronic inflammatory and…
14 Aug 23
Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for $3.2bn upfront
11 Aug 23
The FDA approval was based on results from the talquetamab Phase 2 MonumenTAL-1 study in which Talvey showed…
11 Aug 23
Under the partnership, Lotus will oversee obtaining regulatory approval and will have the sole right to market Adlarity…
11 Aug 23
Preclinical research published in Nature Communications details safety and effectiveness of the investigational therapy now in a Phase…
10 Aug 23
Informally referred to as Eris, the new strain descends from the lineage of XBB.1.9.2, and would pose relatively…
10 Aug 23
At week 12, both Phase 3 studies' primary endpoints of absolute change from baseline in the weekly UAS7…
10 Aug 23
The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently…